Koronis Pharmaceuticals Announces Appointment of Prominent HIV Researcher Courtney Fletcher, Pharm. D., To Scientific Advisory Board and Jeff Parkins As VP, Clinical Development
Posted on: Tuesday, 30 September 2008, 09:01 CDT
Koronis Pharmaceuticals, Inc., a biotechnology company focused on the development of antiviral therapeutics, today announced that Courtney Fletcher, Pharm. D., will join the Company's Scientific Advisory Board and Jeff Parkins has been promoted to Vice President, Clinical Development.
Dr. Fletcher was appointed Dean of the University of Nebraska Medical Center School of Pharmacy in 2007. Prior to that time he served as professor and director of the Antiviral Pharmacology laboratory at University of Colorado. For more than two decades, Dr. Fletcher has focused his research and practice toward the pharmacology of antiviral agents. He is considered one of the leading experts in the clinical pharmacology of nucleosides developed for the treatment of HIV. Dr. Fletcher has authored or co-authored more than 110 manuscripts in peer-reviewed scientific journals and more than 140 research papers for presentation at national and international scientific meetings. Dr. Fletcher is presently a member of the Department of Health and Human Services' Panel on Clinical Practices for the Treatment of HIV Infection. He is a past member of the NIH's AIDS Discovery and Development of Therapeutics Study Section as well as the U.S. Food and Drug Administration's (FDA) Antiviral Drug Advisory Committee.
Dr. Fletcher joins existing Koronis Scientific Advisory Board members including: James Mullins, Ph.D., director of the Genomics core of the University of Washington-Fred Hutchinson Cancer Research Center for AIDS Research and director and principle investigator for the Seattle Primary Infection Program; Larry Loeb, M.D., professor in the Departments of Pathology and Biochemistry and Director of the Gottstein Cancer Research Laboratory at the University of Washington; John Essigmann, Ph.D., Professor of Toxicology and Chemistry at the Massachusetts Institute of Technology; and Donald Bergstrom, Ph.D., Walther Professor of Medicinal Chemistry in the Department of Medicinal Chemistry and Molecular Pharmacology at Purdue University.
Mr. Parkins, who joined Koronis in 2005 as Director of Operations, has over 20 years' experience in pharmaceutical drug and biologics development. Prior to working with Koronis, he managed clinical, manufacturing, quality and project management functions at NeoRx Corporation and served on their executive staff. Mr. Parkins received his B.S. in microbiology from Oregon State University and an M.B.A. from Seattle Pacific University.
About Koronis
Koronis Pharmaceuticals, Inc. is a privately held biotechnology company developing anti-viral therapeutics based on a novel mechanism, Viral Decay Acceleration (VDA). The Company's lead product candidate is KP-1461 for the treatment of human immunodeficiency virus (HIV). The Company also has products in development for the treatment of hepatitis C and RSV. For more information on Koronis, please visit www.koronispharma.com.
Source: Business Wire
Related Articles
- MyChineseLearning Partners with Peking University's Chinese Government Cultural Development Research Center
- Cortria Appoints Gene Cefali, PharmD, PhD As SVP Clinical Pharmacology & Formulation Development
- PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
- DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
- Medifast, Inc. Director of Research & Development Co-Authors Health Book
- StockerYale Names New Director of Research & Development
- Pure H2O Bio-Technologies, Inc. Appoints Former Department of Defense Microbiologist As Director of Research and Development
- AstraZeneca Opens Its First Clinical Pharmacology Unit in the U.S. At the University of Pennsylvania's Penn Presbyterian Medical Center
- NovaShunt AG, a Medical Device Company Focused on Implantable Fluid Management Systems, Appoints Fiona Sander, MSME, As Director of Research & Clinical Affairs
- Viral Genetics, Inc. Hires Director of Research to Lead Product Development and Basic Research Efforts for Lab Facility at Torrey Pines Institute at Molecular Studies
 |
 |
User Comments (0)
RSS Feeds